Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Briggs

Showing results (71-80 of 229) with videos related to

Pageof 23
Sort By:
Pharmacoeconomics|November 29, 2021
Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence ModelsMin Huang, Scott Ramsey, Weiguang Xue, et al.
MDM Policy & Practice|March 28, 2019
Using Nominal Group Technique to Identify Key Attributes of Oncology Treatments for a Discrete Choice ExperimentCamilla Somers, Susan Chimonas, Emma McIntosh, et al.
Pharmacoeconomics|March 6, 2007
Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methodsDiego F Ossa, Andrew Briggs, Emma McIntosh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 10, 2002
Cost-effectiveness and cost-utility of long-term management strategies for heartburnRon Goeree, Bernie J O'Brien, Gordon Blackhouse, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 25, 2026
An Overdue Denunciation of the Minimal Important Difference When Applied to Health State ValuesDavid G T Whitehurst, Andrew Briggs, Andrew J Lloyd, et al.
Current Oncology (Toronto, Ont.)|June 26, 2024
Health Economic Evaluation of Lung Cancer Screening Using a Diagnostic Blood Test: The Early Detection of Cancer of the Lung Scotland (ECLS)Jose Antonio Robles-Zurita, Nicola McMeekin, Frank Sullivan, et al.
Health Economics|December 13, 2016
Twenty-Five Years of Health Economics: A Tribute to Alan Maynard and Acknowledgement of the Work of the Editorial BoardAndrew Briggs, John Hutton, Andrew M Jones, et al.
Health and Quality of Life Outcomes|December 2, 2008
Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitationAndrew Briggs, Diane Wild, Michael Lees, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 21, 2020
Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial DataHelen A Dakin, José Leal, Andrew Briggs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2024
Cost-Effectiveness of Total Neoadjuvant Therapy With Selective Nonoperative Management for Locally Advanced Rectal Cancer: Analysis of Data From the Organ Preservation for Rectal Adenocarcinoma TrialMaria Widmar, Mason McCain, Akriti Mishra Meza, et al.
Pageof 23

Showing results (71-80 of 229) with videos related to

Sort By:
Pageof 23
Pharmacoeconomics|November 29, 2021
Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence ModelsMin Huang, Scott Ramsey, Weiguang Xue, et al.
MDM Policy & Practice|March 28, 2019
Using Nominal Group Technique to Identify Key Attributes of Oncology Treatments for a Discrete Choice ExperimentCamilla Somers, Susan Chimonas, Emma McIntosh, et al.
Pharmacoeconomics|March 6, 2007
Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methodsDiego F Ossa, Andrew Briggs, Emma McIntosh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 10, 2002
Cost-effectiveness and cost-utility of long-term management strategies for heartburnRon Goeree, Bernie J O'Brien, Gordon Blackhouse, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 25, 2026
An Overdue Denunciation of the Minimal Important Difference When Applied to Health State ValuesDavid G T Whitehurst, Andrew Briggs, Andrew J Lloyd, et al.
Current Oncology (Toronto, Ont.)|June 26, 2024
Health Economic Evaluation of Lung Cancer Screening Using a Diagnostic Blood Test: The Early Detection of Cancer of the Lung Scotland (ECLS)Jose Antonio Robles-Zurita, Nicola McMeekin, Frank Sullivan, et al.
Health Economics|December 13, 2016
Twenty-Five Years of Health Economics: A Tribute to Alan Maynard and Acknowledgement of the Work of the Editorial BoardAndrew Briggs, John Hutton, Andrew M Jones, et al.
Health and Quality of Life Outcomes|December 2, 2008
Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitationAndrew Briggs, Diane Wild, Michael Lees, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 21, 2020
Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial DataHelen A Dakin, José Leal, Andrew Briggs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2024
Cost-Effectiveness of Total Neoadjuvant Therapy With Selective Nonoperative Management for Locally Advanced Rectal Cancer: Analysis of Data From the Organ Preservation for Rectal Adenocarcinoma TrialMaria Widmar, Mason McCain, Akriti Mishra Meza, et al.
Pageof 23